Platform session

Evaluation of Ketamine to Reduce Semi-Acute Electrophysiological and Behavioral Compromise following Nerve Agent Exposure

 

Dr. Waylon Weber, Ph.D. Research Scientist at Lovelace biomedical, will explain how his company uses emka TECHNOLOGIES’s rodentPACK along with IOX2 and ecgAUTO software, to perform the evaluation of Ketamine to Reduce Semi-Acute Electrophysiological and Behavioral Compromise following Nerve Agent Exposure.

Platform Session Title: Chemical and Biological Weapons

Session Time: Tuesday March 14, 2017 – 9:30 AM – 12:15 PM

Presentation Time: 3/14/2017 9:50:00 AM

Abstract Title: Evaluation of Ketamine to Reduce Semi-Acute Electrophysiological and Behavioral Compromise following Nerve Agent Exposure

Abstract Number: 1625

Where? Baltimore Convention Center – Room 314
1 W Pratt St. Baltimore MD 21201

See the SOT website.

Other posts you may like

Exhibitor hosted session

easyTEL+, implanted telemetry for large animals & novel in vivo assessments

Printemps de la cardiologie

April 6 - 7, 2017 Nantes - FRANCE

Japanese Respiratory Society

April 21- 23, 2017 Tokyo - JAPAN

Experimental Biology

April 23- 25, 2017 Chicago, IL - USA Booth #315